Navigation Links
Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (OTC Bulletin Board: PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceutical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
5. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
6. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
7. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
8. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
9. Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator ... rumored to be in the beginning stages of an IPO. ... on epilepsy medications with the average cost of a prescription epilepsy drug ... ... Another staggering figure is the fact ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press ... mothers. These illustrations show the diversity of the breastfeeding mothers, using bright ... range of sizes. These illustrations are also available on tote bags, notepads, smartphone ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy ... Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest ... for Tourism Products and Business at TAT said, “Thailand has long been recognized ...
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... consulting services and asset protection assistance to communities in North-Central West Virginia, is ... critical services to at-risk boys in the area. , The Chestnut Mountain Ranch ...
(Date:8/18/2017)... ... 2017 , ... The Golseth Agency, a Texas based insurance management and financial ... regional charity campaign organized to provide support to Christina Upchurch and her two children ... and her children returned from out of town to find her husband passed away ...
Breaking Medicine News(10 mins):